The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000987369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/07/2026
Date registered
Help: Date registered
12/08/2026
Date last updated
Help: Date last updated
12/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Exercise Training on Health Outcomes in Scleroderma (ETHOS) Trial
Scientific title
Exercise as a therapeutic tool for the attenuation of physical function loss and change in health outcomes for people living with Systemic Sclerosis.
Additional trial identifiers [1] 317575 0
Nil
Universal Trial Number (UTN)
Trial acronym
ETHOS
Related trial records

Health condition
Health condition(s) studied:
Systemic Sclerosis 342325 0
Condition category
Condition code
Inflammatory and Immune System 338455 338455 0 0
Connective tissue diseases
Physical Medicine / Rehabilitation 338456 338456 0 0
Physiotherapy

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study will be investigating the efficacy of a 12-week supervised and personalised graded exercise training program in attenuating functional decline and improving health outcomes in systemic sclerosis (SSc) patients. The goal-directed exercise training program will consist of 30-60 minutes of supervised, aerobic and resistance training performed three times per week. Two sessions will be performed in-person in a gym-based setting, and one session will be performed remotely over telehealth. A multi-component exercise approach will be utilised to target the diverse pathophysiological processes that contribute to symptoms of exertional intolerance in individuals with SSc. This will include high-intensity interval training, moderate intensity continuous training, functional circuit training and progressive moderate-to-high intensity resistance training. The exercise prescription will be individualised to each participant's cardiopulmonary exercise test and muscle function assessments as well as their health and disease-specific factors.

Exercise sessions will be prescribed and overseen by an Accredited Exercise Physiologist (AEP) and all training supervised by an appropriately trained AEP and/or Exercise Scientist. The program will consist of one week of familiarisation, and then two 5-week blocks incorporating a progressive increase in exercise duration and/or intensity (i.e progressive overload), which is followed by a de-load/recovery week. Session attendance will be logged and reminders sent out at least at least 24 hours prior to sessions.

Aerobic Training Sessions:
The aerobic component will consist of one continuous steady-state and two interval training session a week with all the sessions being completed on an upright cycle ergometer, with monitoring by the 1-10 rate of perceived exertion (RPE) for dyspnoea, and RPE 6-20 for effort, and/or smartwatches (with heart rate monitoring). For the telehealth session, participants will either use their own equipment (treadmill or cycle ergometer) or will work with the AEP to develop a moderate-intensity aerobic session that the participant can perform independently based on their goals and preferences such as walking outside. All sessions will include a 5-minute light-intensity aerobic warm-up and cool-down. The steady-state sessions will be completed from home with remote supervision via telehealth and will consist of 20-60 minutes of continuous cycling (not including the warm-up or cool-down) at a moderate intensity. The target heart rate for steady state sessions will be set at 5-15 beats/min below the heart rate corresponding to the ventilatory threshold or an RPE for effort of 12-14. The interval sessions will be performed in-person on a cycle ergometer or elliptical trainer, and will consist of 8-20 x alternating work intervals of 30-60 seconds at 80-100% of peak power output from the cardiopulmonary exercise test (CPET), interspersed with 30-90 seconds of unloaded cycling for recovery, and a longer recovery bout incorporated after every 4-5 intervals as required.

Resistance Training Sessions:
As part of the supervised training sessions, participants will complete six compound resistance exercises (three upper-body and three lower-body exercises) which will be centred around functional strength and endurance. Up to 3 sets of up to 15 repetitions will be utilised in the program which will include standard resistance exercises such as leg press, squats, lunges, step-ups, seated rows, chest-press, overhead shoulder press and lat pull-down. Exercise modifications will be made to accommodate participants with limited hand-grip strength and other mobility limitations. In the first 5-weeks of the program, participants will perform 1-3 sets of 12-15 repetitions that can be lifted before fatigue, along with a de-load/recovery week consisting of 1 set of each exercise. As part of the second 5-week block, participants will complete 2-3 sets of 6-12 repetitions until fatigue. Participants will be allowed to rest for 1-2 minutes between each set of exercise. Participants will be monitored using RPE scales, oxygen saturation, and HR throughout the session. The exercises performed in weeks 1-6 will be modified or changed slightly for weeks 7-12 for variety and progression purposes.
For the home-based telehealth session, participants will instead perform a personalised circuit resistance session using exercises based on functional daily tasks such as sit-to-stand, incline push-ups, three-point rows and will consist of minimal equipment (mainly bodyweight and resistance bands).

Intervention code [1] 334373 0
Treatment: Other
Intervention code [2] 334375 0
Prevention
Description of the comparator or control
This will be a randomised waitlist controlled trial with the usual care condition being defined as the participant's individualised usual routine clinical care they receive for SSc that is prescribed outside of this study.
Control group
Active

Outcomes
Primary outcome [1] 345749 0
Change in peak oxygen uptake (VO2peak)
Timepoint [1] 345749 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [1] 463151 0
Change in peak cardiac output
Timepoint [1] 463151 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [2] 463153 0
Change in ventilatory efficiency (VE/VCO2 ratio)
Timepoint [2] 463153 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [3] 463154 0
Change in physical function
Timepoint [3] 463154 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [4] 463155 0
Change in patient-reported daily function
Timepoint [4] 463155 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [5] 463156 0
Change in patient-reported breathlessness
Timepoint [5] 463156 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [6] 463160 0
Change in patient-reported health-related quality of life (HRQoL)
Timepoint [6] 463160 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [7] 463161 0
Change in patient-reported anxiety and depression scale score
Timepoint [7] 463161 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [8] 463172 0
Diffuse myocardial inflammation (T1 and T2 mapping),
Timepoint [8] 463172 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [9] 463173 0
Focal fibrosis (late gadolinium enhancement)
Timepoint [9] 463173 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [10] 463174 0
Change in peak exercise arterio-venous oxygen extraction
Timepoint [10] 463174 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [11] 463176 0
Change in leg skeletal muscle oedema (T1 and T2 mapping).
Timepoint [11] 463176 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [12] 464483 0
Change in leg lean mass
Timepoint [12] 464483 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [13] 464484 0
Change in leg muscle fat infiltration (will be assessed as a composite of intermuscular fat content, intramuscular fat content, and fat fraction)
Timepoint [13] 464484 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [14] 464485 0
Change in peak exercise ejection fraction
Timepoint [14] 464485 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [15] 464486 0
Change in peak exercise stroke volume
Timepoint [15] 464486 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [16] 464487 0
Change in resting left-ventricular end-diastolic volume
Timepoint [16] 464487 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [17] 464488 0
Change in resting right-ventricular end-diastolic volume
Timepoint [17] 464488 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [18] 464489 0
Change in left-ventricular mass
Timepoint [18] 464489 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [19] 465309 0
Diffuse myocardial fibrosis (T1 and T2 mapping),
Timepoint [19] 465309 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)
Secondary outcome [20] 465312 0
Change in leg skeletal muscle fibrosis (T1 and T2 mapping).
Timepoint [20] 465312 0
Baseline, 3-month (first intervention group; first control group), 6-month (second intervention group; second control group)

Eligibility
Key inclusion criteria
• Males and females with a confirmed American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification of SSc
• Aged 18+ years
• Fluent in the English language
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Absolute contraindication to exercise
• Inability to cycle on an upright bike
• Renal impairment (eGFR <30mL/min/1.73m2)
• Pulmonary Arterial Hypertension
• Current Atrial Fibrillation
• Heart failure and/or LVEF <50%
• Severe ILD defined as Forced Vital Capacity (FVC) <45% (predicted), single-breath carbon monoxide diffusing lung capacity (DLCO) corrected for haemoglobin <30% (predicted)
• Contraindication to MRI (pacemaker, defibrillator or any implanted foreign body, severe claustrophobia)
• Pregnancy or currently breastfeeding
• Gadolinium allergy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random sequence
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Waitlist controlled design: Participants will be allocated to either immediate intervention (months 0-3), or will undergo a 3-month control period (months 0-3) before undertaking the intervention (months 4-6).
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Statistical data analysis will be performed on an intention to treat basis, using Jamovi open-source software (The Jamovi Project, Sydney, NSW, Australia) and R studio (PBC, Boston, MA, USA). GraphPad Prism (GraphPad Software, Boston MA, USA) will also be utilised to visualise data. We will also perform a per-protocol analysis including only participants who completed >66% of the prescribed sessions (equivalent to 2 out of 3 prescribed sessions) as we have done previously. Data will be presented as mean ± SD with normativity and homogeneity testing through the Shapiro-Wilk and Levene’s test, respectively. Comparisons of the two groups will be done through independent t-tests and Chi-squared tests. A generalised mixed linear model will be utilised to assess the efficacy of the 12-week exercise intervention on the primary and secondary study outcomes at 3-months, with participants included as a random effect, and group allocation and timepoint as fixed effects.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29642 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment postcode(s) [1] 45983 0
3065 - Fitzroy

Funding & Sponsors
Funding source category [1] 322133 0
Government body
Name [1] 322133 0
National Health and Medical Research Council of Australia Investigator Grant
Country [1] 322133 0
Australia
Primary sponsor type
Other
Name
St Vincent's Institute of Medical Research
Address
Country
Australia
Secondary sponsor category [1] 325430 0
None
Name [1] 325430 0
Address [1] 325430 0
Country [1] 325430 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320662 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 320662 0
Ethics committee country [1] 320662 0
Australia
Date submitted for ethics approval [1] 320662 0
02/12/2025
Approval date [1] 320662 0
31/03/2026
Ethics approval number [1] 320662 0
2025/PID00568

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151210 0
Prof Andre La Gerche
Address 151210 0
St Vincent's Institute of Medical Research: 9 Princes Street, Fitzroy VIC 3065
Country 151210 0
Australia
Phone 151210 0
+61 481300929
Fax 151210 0
Email 151210 0
Contact person for public queries
Name 151211 0
Andre La Gerche
Address 151211 0
St Vincent's Institute of Medical Research: 9 Princes Street, Fitzroy VIC 3065
Country 151211 0
Australia
Phone 151211 0
+61 481300929
Fax 151211 0
Email 151211 0
Contact person for scientific queries
Name 151212 0
Andre La Gerche
Address 151212 0
St Vincent's Institute of Medical Research: 9 Princes Street, Fitzroy VIC 3065
Country 151212 0
Australia
Phone 151212 0
+61 481300929
Fax 151212 0
Email 151212 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.